KEY ELIGIBILITY CRITERIA

        Inclusion Criteria:

          -  Adults ≥18 years of age at the time of study consent

          -  Subjects with any of the following eligible solid tumor diagnoses as confirmed by
             cytology or histology:

               -  Escalation Cohorts (Part A): Subjects with solid tumors from pre-specified tumor
                  types (gynecological cancers [including ovarian, endometrial, cervix, vagina,
                  vulva], gastric [adenocarcinoma], colon [MSIlow],(MSIlow and CPI refractory
                  MSIhigh) ], Colon (MSIlow and CPI refractory MSIhigh), lung [adenocarcinoma],
                  renal [clear cell and non-clear cell], breast [TNBC and HR+ HER-2-] with
                  metastatic disease that is relapsed or refractory to at least one line of
                  metastatic therapy (including a CPI-either alone or in combination- if approved
                  for that indication, and not eligible for other targeted therapies specific for
                  their tumor type). Lung adenocarcinoma subjects who are relapsed or refractory to
                  platinum-based chemotherapy in addition to prior treatment with PD-1/PD-L1 or who
                  give informed consent to forego such therapy.

               -  Expansion Cohorts (Part B): Subjects with advanced solid tumors selected from
                  prespecified histologic subgroups identified in Part A.

          -  Subjects must provide an original, diagnostic tumor sample to determine TREM2
             expression (Investigators have verified source and availability of archival tissue
             during screening). Subjects without an archival tissue sample will only be eligible if
             they choose and consent to provide a CNB of primary or a metastatic lesion required
             for part B, used in Part A only if an archival specimen unavailable.

          -  Subjects must have documented disease progression (Part A, including prior treatment
             with a CPI (alone or in combination), if approved for that indication

          -  Measurable disease by RECIST 1.1

          -  All acute toxic effects of any prior antitumor therapy, including immunotherapy,
             resolved to Grade ≤ 1 or < 2 if controlled on medications (eg thyroid replacement
             therapy) before the start of study drug dosing

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

          -  Coagulation: International Normalized Ratio (INR) ≤ 1.3, unless on a therapeutic
             anticoagulant

          -  Adequate hematologic function defined as follows: Platelets ≥ 100 x 109/L; Hemoglobin
             ≥ 9.0 g/dL; ANC ≥ 1.5 x 109/L (without any granulocytic growth factors within previous
             7 days of the screening hematologic laboratory values)

          -  Adequate hepatic function defined as follows: AST / ALT ≤ 2.5 x upper limit of normal
             (ULN) (if liver metastases are present, ≤ 5 x ULN); Total or conjugated bilirubin ≤
             1.5 x ULN

          -  Adequate renal function defined as follows: Serum Creatinine ≤ 2 x ULN or creatinine
             clearance (CrCl) ≥45 mL/min as calculated by the Cockroft-Gault method

        Exclusion Criteria:

          -  Patient is a candidate for molecularly targeted therapy (e.g. drugs targeting EGFR,
             EGFR, ALK, ROS-1, NTRK, MET, RET and BRAF V600E, Her2neu)). Applies to enrolled
             subjects on both Part A and Part B of the study.

          -  History of autoimmune disorder requiring ongoing or intermittent disease-modifying
             therapy

          -  Stable treated or asymptomatic brain metastases for at least 3 months documented by
             brain imaging prior to enrollment

          -  Uncontrolled intercurrent illness including, but not limited to, active or chronic
             bleeding event within 28 days prior to first dose of study drug, or psychiatric
             illness/social situation that would limit compliance with study requirements as judged
             by treating physician

          -  Decompensated liver disease as evidenced by hepatic encephalopathy or coagulopathy

          -  Active angina or Class III or IV CHF (NYHA CHF Functional Classification System) or
             clinically significant cardiac disease within 12 months of first dose of study drug,
             including MI, unstable angina, Grade 2 or greater peripheral vascular disease, CHF,
             uncontrolled HTN, or arrhythmias not controlled by medication

          -  Any anti-cancer therapy, including small molecules, immunotherapy, chemotherapy,
             monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer within
             14 days, of first dose of study drug

          -  Part B: excluding refractory lung cancer subjects who have progressed within 3 months
             of initiating chemotherapy-doublet regimens or lung cancer subjects who have
             progressed within 6 months of initiation immunotherapy-chemotherapy combination
             treatment

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.